CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nyrada Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nyrada Inc
Suite 2, Level 3,, 828 Pacific Highway
Phone: +61 294983390p:+61 294983390 GORDON, NSW  2072  Australia Ticker: NYRNYR
Business Summary
Nyrada Inc. is a biotechnology company focused on the discovery and development of small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The Company’s lead candidate, NYR-BI03, has shown efficacy in both neuroprotection and cardioprotection. The NYR-BI03 has potential to fill a significant treatment gap targeting ischemia-reperfusion injury. NYR-BI03 additionally has the potential to provide dual protection for both the heart and brain from ischemia-reperfusion damage, helping prevent heart failure and neurological damage. Its Neuroprotection Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischaemic stroke. Its Cardioprotection Program is a cardioprotectant drug to reduce the damage to the heart following myocardial infarction (heart attack).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20246/30/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

General Information
Outstanding Shares: 182,208,698 (As of 6/30/2024)
Shareholders: 1,648
Stock Exchange: ASX
Fax Number: +61 290531999


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025